Park RW - Search Results

1

Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate.

Lee DY, Kim SK, Kim YS, Son DH, Nam JH, Kim IS, Park RW, Kim SY, Byun Y. Lee DY, et al. Among authors: park rw. J Control Release. 2007 Apr 23;118(3):310-7. doi: 10.1016/j.jconrel.2006.12.031. Epub 2007 Jan 12. J Control Release. 2007. PMID: 17291620

2

Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery.

Park JH, Kwon S, Nam JO, Park RW, Chung H, Seo SB, Kim IS, Kwon IC, Jeong SY. Park JH, et al. Among authors: park rw. J Control Release. 2004 Mar 24;95(3):579-88. doi: 10.1016/j.jconrel.2003.12.020. J Control Release. 2004. PMID: 15023468

3

Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel.

Kim JH, Kim YS, Kim S, Park JH, Kim K, Choi K, Chung H, Jeong SY, Park RW, Kim IS, Kwon IC. Kim JH, et al. Among authors: park jh, park rw. J Control Release. 2006 Mar 10;111(1-2):228-34. doi: 10.1016/j.jconrel.2005.12.013. Epub 2006 Feb 3. J Control Release. 2006. PMID: 16458988

4

betaig-h3 triggers signaling pathways mediating adhesion and migration of vascular smooth muscle cells through alphavbeta5 integrin.

Lee BH, Bae JS, Park RW, Kim JE, Park JY, Kim IS. Lee BH, et al. Among authors: park jy, park rw. Exp Mol Med. 2006 Apr 30;38(2):153-61. doi: 10.1038/emm.2006.19. Exp Mol Med. 2006. PMID: 16672769

5

Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity.

Park K, Lee GY, Kim YS, Yu M, Park RW, Kim IS, Kim SY, Byun Y. Park K, et al. Among authors: park rw. J Control Release. 2006 Sep 12;114(3):300-6. doi: 10.1016/j.jconrel.2006.05.017. Epub 2006 May 25. J Control Release. 2006. PMID: 16884806

6

Antiangiogenic effect of bile acid acylated heparin derivative.

Park K, Kim YS, Lee GY, Nam JO, Lee SK, Park RW, Kim SY, Kim IS, Byun Y. Park K, et al. Among authors: park rw. Pharm Res. 2007 Jan;24(1):176-85. doi: 10.1007/s11095-006-9139-6. Epub 2006 Nov 16. Pharm Res. 2007. PMID: 17109210

7

Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy.

Yu MK, Lee DY, Kim YS, Park K, Park SA, Son DH, Lee GY, Nam JH, Kim SY, Kim IS, Park RW, Byun Y. Yu MK, et al. Among authors: park sa, park rw, park k. Pharm Res. 2007 Apr;24(4):705-14. doi: 10.1007/s11095-006-9190-3. Epub 2007 Feb 21. Pharm Res. 2007. PMID: 17318418

8

The attenuation of experimental lung metastasis by a bile acid acylated-heparin derivative.

Park K, Ki Lee S, Hyun Son D, Ah Park S, Kim K, Won Chang H, Jeong EJ, Park RW, Kim IS, Chan Kwon I, Byun Y, Kim SY. Park K, et al. Among authors: park rw. Biomaterials. 2007 Jun;28(16):2667-76. doi: 10.1016/j.biomaterials.2007.02.001. Epub 2007 Mar 1. Biomaterials. 2007. PMID: 17335894

9

Combination therapy of heparin-deoxycholic acid conjugate and doxorubicin against squamous cell carcinoma and B16F10 melanoma.

Park K, Lee GY, Park RW, Kim IS, Kim SY, Byun Y. Park K, et al. Among authors: park rw. Pharm Res. 2008 Feb;25(2):268-76. doi: 10.1007/s11095-007-9366-5. Epub 2007 Jul 11. Pharm Res. 2008. PMID: 17619999

10

Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.

Ko J, Park K, Kim YS, Kim MS, Han JK, Kim K, Park RW, Kim IS, Song HK, Lee DS, Kwon IC. Ko J, et al. Among authors: park rw, park k. J Control Release. 2007 Nov 6;123(2):109-15. doi: 10.1016/j.jconrel.2007.07.012. Epub 2007 Aug 8. J Control Release. 2007. PMID: 17894942

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

359 results

Search Page

Filters